These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

289 related items for PubMed ID: 15302906

  • 1. Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors.
    Fizazi K, Culine S, Kramar A, Amato RJ, Bouzy J, Chen I, Droz JP, Logothetis CJ.
    J Clin Oncol; 2004 Oct 01; 22(19):3868-76. PubMed ID: 15302906
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Cluster analysis of p53 and Ki67 expression, apoptosis, alpha-fetoprotein, and human chorionic gonadotrophin indicates a favorable prognostic subgroup within the embryonal carcinoma germ cell tumor.
    Mazumdar M, Bacik J, Tickoo SK, Dobrzynski D, Donadio A, Bajorin D, Motzer R, Reuter V, Bosl GJ.
    J Clin Oncol; 2003 Jul 15; 21(14):2679-88. PubMed ID: 12860944
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Drug dose delivery and treatment outcome relationship in standard bleomycin, etoposide and cisplatin combination chemotherapy in nonseminomatous germ cell tumor patients.
    Gutierrez-Delgado F, Titov DA, Tjulandin SA, Garin AM.
    Neoplasma; 1999 Jul 15; 46(3):190-5. PubMed ID: 10613596
    [Abstract] [Full Text] [Related]

  • 9. Early identification of therapeutic failure in nonseminomatous germ cell tumors by assessing serum tumor marker decline during chemotherapy: still not ready for routine clinical use.
    Toner GC.
    J Clin Oncol; 2004 Oct 01; 22(19):3842-5. PubMed ID: 15302908
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours.
    Fosså SD, Stenning SP, Gerl A, Horwich A, Clark PI, Wilkinson PM, Jones WG, Williams MV, Oliver RT, Newlands ES, Mead GM, Cullen MH, Kaye SB, Rustin GJ, Cook PA.
    Br J Cancer; 1999 Jul 01; 80(9):1392-9. PubMed ID: 10424741
    [Abstract] [Full Text] [Related]

  • 12. [Retroperitoneal lymphadenectomy in disseminated non-seminoma germinogenic testicular tumors after chemotherapy in patients with elevated serum tumor markers].
    Matveev VB, Volkova MI, Cherniev VA, Figurin KM, Mitin AV.
    Urologiia; 2010 Jul 01; (3):41-7. PubMed ID: 20734877
    [Abstract] [Full Text] [Related]

  • 13. The prognostic value of tumor markers in newly diagnosed patients with primary central nervous system germ cell tumors.
    Kim A, Ji L, Balmaceda C, Diez B, Kellie SJ, Dunkel IJ, Gardner SL, Sposto R, Finlay JL.
    Pediatr Blood Cancer; 2008 Dec 01; 51(6):768-73. PubMed ID: 18802946
    [Abstract] [Full Text] [Related]

  • 14. Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy.
    Mazumdar M, Bajorin DF, Bacik J, Higgins G, Motzer RJ, Bosl GJ.
    J Clin Oncol; 2001 May 01; 19(9):2534-41. PubMed ID: 11331333
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era.
    Sonneveld DJ, Hoekstra HJ, van der Graaf WT, Sluiter WJ, Mulder NH, Willemse PH, Koops HS, Sleijfer DT.
    Cancer; 2001 Apr 01; 91(7):1304-15. PubMed ID: 11283931
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection.
    Beck SD, Foster RS, Bihrle R, Einhorn LH, Donohue JP.
    J Clin Oncol; 2005 Sep 01; 23(25):6149-56. PubMed ID: 16135481
    [Abstract] [Full Text] [Related]

  • 19. Tumor marker levels in post-chemotherapy cystic masses: clinical implications for patients with germ cell tumors.
    Beck SD, Patel MI, Sheinfeld J.
    J Urol; 2004 Jan 01; 171(1):168-71. PubMed ID: 14665869
    [Abstract] [Full Text] [Related]

  • 20. Significance of elevated preoperative alpha-fetoprotein in postchemotherapy residual tumor resection for the disseminated germ cell tumors.
    Kobayashi T, Kawakita M, Terachi T, Habuchi T, Ogawa O, Kamoto T.
    J Surg Oncol; 2006 Dec 01; 94(7):619-23. PubMed ID: 17111392
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.